Shore Capital's sale of EyeSouth Partners shows off lower-mid-market buy-and-build model

The Chicago firm reportedly grew the target's EBITDA from $2m in 2017 to $70m when sold to Olympus Partners in September.

DealsFeaturedBusiness servicesHealthcareFeaturedTop Stories